Search results
Added:
3 years ago
Natriuretic peptides (NPs) are well established in the diagnostic process of heart failure (HF). Low levels of NPs are particularly useful to exclude heart failure (HF). Numerous studies, predominantly in patients presenting with acute onset of symptoms suspected of HF, have convincingly shown the value of NPs in this regard. A meta-analysis published in 2015 clearly summarised the value of brain…
View more
Added:
3 years ago
Detailed phenotyping of ventricular–arterial coupling (VAC) and systemic arterial haemodynamics provide important insights into the pathophysiology of left ventricular (LV) energetics, remodelling and fibrosis, and systolic and diastolic dysfunction in various disease states including heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).1…
View more
Added:
3 years ago
Although the first study on biomarker-guided therapy of chronic heart failure (HF) was published 15 years ago,1 there is still no real proof of the superiority of this approach as compared with standard therapy. The guidelines of the European Society of Cardiology simply state that: “several RCTs that evaluated natriuretic peptide-guided treatment (intensifying treatment in order to lower peptide…
View more
Added:
6 months ago
ESC 23 – Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Prof Giuseppe Rosano (St George’s Hospitals NHS Trust University of London, UK), President of HFA to distil the key messages from the 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
Prof Rosano summarises the retained ejection fraction…
View more
Added:
3 years ago
Heart failure (HF) is one of the most common reasons for admission to hospital. It is associated with long in-patient stays, and has a high in-hospital and post-discharge morbidity and mortality, whether left ventricular ejection fraction (LVEF) is reduced (HFREF) or normal (HeFNEF).1,2 Congestion, or fluid overload, is a classic clinical feature of patients presenting with HF. In some patients,…
View more
Added:
3 years ago
In developed countries, it is estimated that 1–2 % of the adult population has heart failure (HF), with the prevalence increasing to more than 10 % in those aged >70 years.1 Despite advances in therapies for heart failure with reduced ejection fraction (HFrEF), it remains a condition associated with significant morbidity and mortality, punctuated by episodes of unplanned hospitalisation.2
HF…
View more
Added:
7 years ago
Felipe Martinez discusses "New drugs for the management of chronic heart failure" at the 2016 ESC Congress in Rome, Italy
View more
Added:
3 years ago
ESC Guidelines for Patient Self-management in Chronic Heart Failure
The gold-standard of patient self-management in chronic heart failure (CHF) can be defined as “daily activities that maintain clinical stability”.1 This requires that patients monitor their symptoms, adhere to their medication, diet and exercise regimens and manage symptoms by recognising changes and responding by either…
View more
Added:
3 years ago
Introduction
Advances in heart failure medical therapy over the past few decades have improved the prognosis of patients with this condition. Despite this, heart failure remains a significant burden to the medical system as the incidence of heart failure hospitalisation continues to rise.1 Diuretics have been a mainstay of therapy in heart failure to relieve congestion and improve symptoms…
View more
